Cargando…
Antimicrobial Activity of Gallium Compounds on ESKAPE Pathogens
ESKAPE bacteria are a major cause of multidrug-resistant infections, and new drugs are urgently needed to combat these pathogens. Given the importance of iron in bacterial physiology and pathogenicity, iron uptake and metabolism have become attractive targets for the development of new antibacterial...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6139391/ https://www.ncbi.nlm.nih.gov/pubmed/30250828 http://dx.doi.org/10.3389/fcimb.2018.00316 |
_version_ | 1783355509337751552 |
---|---|
author | Hijazi, Sarah Visaggio, Daniela Pirolo, Mattia Frangipani, Emanuela Bernstein, Lawrence Visca, Paolo |
author_facet | Hijazi, Sarah Visaggio, Daniela Pirolo, Mattia Frangipani, Emanuela Bernstein, Lawrence Visca, Paolo |
author_sort | Hijazi, Sarah |
collection | PubMed |
description | ESKAPE bacteria are a major cause of multidrug-resistant infections, and new drugs are urgently needed to combat these pathogens. Given the importance of iron in bacterial physiology and pathogenicity, iron uptake and metabolism have become attractive targets for the development of new antibacterial drugs. In this scenario, the FDA-approved iron mimetic metal Gallium [Ga(III)] has been successfully repurposed as an antimicrobial drug. Ga(III) disrupts ferric iron-dependent metabolic pathways, thereby inhibiting microbial growth. This work provides the first comparative assessment of the antibacterial activity of Ga(NO(3))(3) (GaN), Ga(III)-maltolate (GaM), and Ga(III)-protoporphyrin IX (GaPPIX), belonging to the first-, second- and third-generation of Ga(III) formulations, respectively, on ESKAPE species, including reference strains and multidrug-resistant (MDR) clinical isolates. In addition to the standard culture medium Mueller Hinton broth (MHB), iron-depleted MHB (DMHB) and RPMI-1640 supplemented with 10% human serum (HS) (RPMI-HS) were also included in Ga(III)-susceptibility tests, because of their different nutrient and iron contents. All ESKAPE species were resistant to all Ga(III) compounds in MHB and DMHB (MIC > 32 μM), except Staphylococcus aureus and Acinetobacter baumannii, which were susceptible to GaPPIX. Conversely, the antibacterial activity of GaN and GaM was very evident in RPMI-HS, in which the low iron content and the presence of HS better mimic the in vivo environment. In RPMI-HS about 50% of the strains were sensitive (MIC < 32) to GaN and GaM, both compounds showing a similar spectrum of activity, although GaM was more effective than GaN. In contrast, GaPPIX lost its antibacterial activity in RPMI-HS likely due to the presence of albumin, which binds GaPPIX and counteracts its inhibitory effect. We also demonstrated that the presence of multiple heme-uptake systems strongly influences GaPPIX susceptibility in A. baumannii. Interestingly, GaN and GaM showed only a bacteriostatic effect, whereas GaPPIX exerted a bactericidal activity on susceptible strains. Altogether, our findings raise hope for the future development of Ga(III)-based compounds in the treatment of infections caused by multidrug-resistant ESKAPE pathogens. |
format | Online Article Text |
id | pubmed-6139391 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-61393912018-09-24 Antimicrobial Activity of Gallium Compounds on ESKAPE Pathogens Hijazi, Sarah Visaggio, Daniela Pirolo, Mattia Frangipani, Emanuela Bernstein, Lawrence Visca, Paolo Front Cell Infect Microbiol Cellular and Infection Microbiology ESKAPE bacteria are a major cause of multidrug-resistant infections, and new drugs are urgently needed to combat these pathogens. Given the importance of iron in bacterial physiology and pathogenicity, iron uptake and metabolism have become attractive targets for the development of new antibacterial drugs. In this scenario, the FDA-approved iron mimetic metal Gallium [Ga(III)] has been successfully repurposed as an antimicrobial drug. Ga(III) disrupts ferric iron-dependent metabolic pathways, thereby inhibiting microbial growth. This work provides the first comparative assessment of the antibacterial activity of Ga(NO(3))(3) (GaN), Ga(III)-maltolate (GaM), and Ga(III)-protoporphyrin IX (GaPPIX), belonging to the first-, second- and third-generation of Ga(III) formulations, respectively, on ESKAPE species, including reference strains and multidrug-resistant (MDR) clinical isolates. In addition to the standard culture medium Mueller Hinton broth (MHB), iron-depleted MHB (DMHB) and RPMI-1640 supplemented with 10% human serum (HS) (RPMI-HS) were also included in Ga(III)-susceptibility tests, because of their different nutrient and iron contents. All ESKAPE species were resistant to all Ga(III) compounds in MHB and DMHB (MIC > 32 μM), except Staphylococcus aureus and Acinetobacter baumannii, which were susceptible to GaPPIX. Conversely, the antibacterial activity of GaN and GaM was very evident in RPMI-HS, in which the low iron content and the presence of HS better mimic the in vivo environment. In RPMI-HS about 50% of the strains were sensitive (MIC < 32) to GaN and GaM, both compounds showing a similar spectrum of activity, although GaM was more effective than GaN. In contrast, GaPPIX lost its antibacterial activity in RPMI-HS likely due to the presence of albumin, which binds GaPPIX and counteracts its inhibitory effect. We also demonstrated that the presence of multiple heme-uptake systems strongly influences GaPPIX susceptibility in A. baumannii. Interestingly, GaN and GaM showed only a bacteriostatic effect, whereas GaPPIX exerted a bactericidal activity on susceptible strains. Altogether, our findings raise hope for the future development of Ga(III)-based compounds in the treatment of infections caused by multidrug-resistant ESKAPE pathogens. Frontiers Media S.A. 2018-09-10 /pmc/articles/PMC6139391/ /pubmed/30250828 http://dx.doi.org/10.3389/fcimb.2018.00316 Text en Copyright © 2018 Hijazi, Visaggio, Pirolo, Frangipani, Bernstein and Visca. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Cellular and Infection Microbiology Hijazi, Sarah Visaggio, Daniela Pirolo, Mattia Frangipani, Emanuela Bernstein, Lawrence Visca, Paolo Antimicrobial Activity of Gallium Compounds on ESKAPE Pathogens |
title | Antimicrobial Activity of Gallium Compounds on ESKAPE Pathogens |
title_full | Antimicrobial Activity of Gallium Compounds on ESKAPE Pathogens |
title_fullStr | Antimicrobial Activity of Gallium Compounds on ESKAPE Pathogens |
title_full_unstemmed | Antimicrobial Activity of Gallium Compounds on ESKAPE Pathogens |
title_short | Antimicrobial Activity of Gallium Compounds on ESKAPE Pathogens |
title_sort | antimicrobial activity of gallium compounds on eskape pathogens |
topic | Cellular and Infection Microbiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6139391/ https://www.ncbi.nlm.nih.gov/pubmed/30250828 http://dx.doi.org/10.3389/fcimb.2018.00316 |
work_keys_str_mv | AT hijazisarah antimicrobialactivityofgalliumcompoundsoneskapepathogens AT visaggiodaniela antimicrobialactivityofgalliumcompoundsoneskapepathogens AT pirolomattia antimicrobialactivityofgalliumcompoundsoneskapepathogens AT frangipaniemanuela antimicrobialactivityofgalliumcompoundsoneskapepathogens AT bernsteinlawrence antimicrobialactivityofgalliumcompoundsoneskapepathogens AT viscapaolo antimicrobialactivityofgalliumcompoundsoneskapepathogens |